Antibiotic-Loaded Gold Nanoparticles: A Nano-Arsenal against ESBL Producer-Resistant Pathogens.

ESBLs antibiotic resistance bacterial pathogens gold nanoparticles nano-therapeutics

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
28 Jan 2023
Historique:
received: 07 12 2022
revised: 21 01 2023
accepted: 26 01 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

The advent of new antibiotics has helped clinicians to control severe bacterial infections. Despite this, inappropriate and redundant use of antibiotics, inadequate diagnosis, and smart resistant mechanisms developed by pathogens sometimes lead to the failure of treatment strategies. The genotypic analysis of clinical samples revealed that the rapid spread of extended-spectrum β-lactamases (ESBLs) genes is one of the most common approaches acquired by bacterial pathogens to become resistant. The scenario compelled the researchers to prioritize the design and development of novel and effective therapeutic options. Nanotechnology has emerged as a plausible groundbreaking tool against resistant infectious pathogens. Numerous reports suggested that inorganic nanomaterials, specifically gold nanoparticles (AuNPs), have converted unresponsive antibiotics into potent ones against multi-drug resistant pathogenic strains. Interestingly, after almost two decades of exhaustive preclinical evaluations, AuNPs are gradually progressively moving ahead toward clinical evaluations. However, the mechanistic aspects of the antibacterial action of AuNPs remain an unsolved puzzle for the scientific fraternity. Thus, the review covers state-of-the-art investigations pertaining to the efficacy of AuNPs as a tool to overcome ESBLs acquired resistance, their applicability and toxicity perspectives, and the revelation of the most appropriate proposed mechanism of action. Conclusively, the trend suggested that antibiotic-loaded AuNPs could be developed into a promising interventional strategy to limit and overcome the concerns of antibiotic-resistance.

Identifiants

pubmed: 36839753
pii: pharmaceutics15020430
doi: 10.3390/pharmaceutics15020430
pmc: PMC9967522
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Nanotechnology. 2020 May 22;31(21):215604
pubmed: 32018229
Chem Rev. 2021 May 12;121(9):5158-5192
pubmed: 33724823
Adv Drug Deliv Rev. 2008 Aug 17;60(11):1307-1315
pubmed: 18555555
Nanomaterials (Basel). 2020 Sep 30;10(10):
pubmed: 33008104
Mater Sci Eng C Mater Biol Appl. 2012 Aug 1;32(6):1571-7
pubmed: 24364962
Small. 2018 Oct;14(42):e1801451
pubmed: 30239120
Polymers (Basel). 2022 Feb 16;14(4):
pubmed: 35215685
Mol Microbiol. 2001 Jul;41(1):189-98
pubmed: 11454211
Adv Pharm Bull. 2017 Sep;7(3):479-483
pubmed: 29071232
Mater Sci Eng C Mater Biol Appl. 2019 Mar;96:693-707
pubmed: 30606583
Materials (Basel). 2022 Aug 18;15(16):
pubmed: 36013845
Eur J Neurol. 2008 Jul;15(7):649-59
pubmed: 18582342
Crit Care Res Pract. 2012;2012:625170
pubmed: 21766013
Biotechnol Appl Biochem. 2010 Jan 25;55(1):29-35
pubmed: 19929854
Lett Appl Microbiol. 2018 Dec;67(6):537-543
pubmed: 30269338
Indian J Med Microbiol. 2005 Jan;23(1):20-3
pubmed: 15928416
J Am Chem Soc. 2010 Apr 7;132(13):4678-84
pubmed: 20225865
Nanomaterials (Basel). 2022 Oct 18;12(20):
pubmed: 36296833
J Photochem Photobiol B. 2020 Aug;209:111923
pubmed: 32559647
RSC Adv. 2014 Dec 8;4(94):51904-51910
pubmed: 25580243
J Clin Microbiol. 2011 Jan;49(1):189-94
pubmed: 21048014
Chem Rev. 2007 Nov;107(11):4797-862
pubmed: 17999554
Adv Colloid Interface Sci. 2019 Sep;271:101989
pubmed: 31330396
Res Microbiol. 2004 Jul-Aug;155(6):409-21
pubmed: 15249058
Drug Deliv Transl Res. 2023 Feb;13(2):378-385
pubmed: 36045273
Nanomedicine (Lond). 2007 Oct;2(5):681-93
pubmed: 17976030
PLoS One. 2021 May 20;16(5):e0251594
pubmed: 34014957
IET Nanobiotechnol. 2016 Aug;10(4):190-4
pubmed: 27463788
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(3):286-327
pubmed: 26072980
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:82-9
pubmed: 18154531
Nanomaterials (Basel). 2020 Feb 09;10(2):
pubmed: 32050443
Water Res. 2008 Nov;42(18):4591-602
pubmed: 18804836
Life Sci. 2016 May 15;153:171-9
pubmed: 27101926
Expert Rev Anti Infect Ther. 2008 Oct;6(5):671-83
pubmed: 18847405
Lancet Infect Dis. 2011 Sep;11(9):692-701
pubmed: 21659004
Nano Converg. 2016;3(1):1
pubmed: 28191411
Curr Microbiol. 2002 Dec;45(6):446-55
pubmed: 12402087
Nanotoxicology. 2010 Mar;4(1):120-37
pubmed: 20795906
Int J Nanomedicine. 2017 Mar 29;12:2457-2468
pubmed: 28408817
Nanomaterials (Basel). 2016 Apr 14;6(4):
pubmed: 28335198
Molecules. 2017 Aug 31;22(9):
pubmed: 28858253
Front Microbiol. 2016 May 02;7:607
pubmed: 27330535
Adv Healthc Mater. 2013 Apr;2(4):599-606
pubmed: 23184755
RSC Adv. 2015;5(128):105551-105559
pubmed: 26877871
Materials (Basel). 2022 Jan 31;15(3):
pubmed: 35161053
P T. 2015 May;40(5):344-52
pubmed: 25987823
Angew Chem Int Ed Engl. 2014 Feb 10;53(7):1756-89
pubmed: 24421264
Chem Soc Rev. 2012 Apr 7;41(7):2943-70
pubmed: 22388295
J Nanosci Nanotechnol. 2016 Jun;16(6):6393-9
pubmed: 27427725
Sci Rep. 2017 Jun 23;7(1):4131
pubmed: 28646143
J Am Chem Soc. 2012 Sep 5;134(35):14542-54
pubmed: 22920241
Biomed Pharmacother. 2018 Nov;107:7-18
pubmed: 30075371
Colloids Surf B Biointerfaces. 2018 Jul 1;167:1-7
pubmed: 29625418
Biomaterials. 2008 Apr;29(12):1912-9
pubmed: 18242692
Microb Drug Resist. 2019 Oct;25(8):1155-1163
pubmed: 31613200
J Am Chem Soc. 2011 Mar 23;133(11):4132-9
pubmed: 21344925
J Cell Biochem. 2017 Sep;118(9):2802-2808
pubmed: 28181300
Antimicrob Agents Chemother. 2011 Apr;55(4):1485-93
pubmed: 21282452
Colloids Surf B Biointerfaces. 2008 Oct 15;66(2):274-80
pubmed: 18722754
Sci Rep. 2021 Jul 12;11(1):14296
pubmed: 34253804
Nat Mater. 2008 Jul;7(7):588-95
pubmed: 18500347
Int J Mol Sci. 2019 May 18;20(10):
pubmed: 31109079
Antimicrob Resist Infect Control. 2019 Feb 15;8:39
pubmed: 30815254
Nanoscale. 2013 Mar 7;5(5):1882-93
pubmed: 23348618
Mater Sci Eng C Mater Biol Appl. 2016 Apr 1;61:720-7
pubmed: 26838902
Int J Mol Sci. 2009 Nov 20;10(10):4198-4209
pubmed: 20057940
AIMS Microbiol. 2018 Jun 26;4(3):482-501
pubmed: 31294229
J Am Chem Soc. 2010 Sep 8;132(35):12349-56
pubmed: 20707350
Nanomaterials (Basel). 2021 Mar 22;11(3):
pubmed: 33809859
Nanomedicine. 2012 Jan;8(1):1-7
pubmed: 22094122
ACS Appl Mater Interfaces. 2019 Sep 11;11(36):32599-32604
pubmed: 31449379
J Nanopart Res. 2010 Sep;12(7):2313-2333
pubmed: 21170131
Langmuir. 2004 Mar 2;20(5):1909-14
pubmed: 15801462
Environ Res. 2021 Aug;199:111321
pubmed: 33989619
PLoS One. 2009;4(5):e5453
pubmed: 19434239
Appl Environ Microbiol. 2012 Apr;78(8):2768-74
pubmed: 22286985
Adv Mater. 2020 Dec;32(52):e2005679
pubmed: 33179362
Small. 2008 Jan;4(1):153-9
pubmed: 18081130
Nanomedicine (Lond). 2018 Jun;13(12):1405-1416
pubmed: 29972649
Small. 2007 Nov;3(11):1941-9
pubmed: 17963284
Small. 2009 Mar;5(6):701-8
pubmed: 19226599
Nanoscale Res Lett. 2009 May 8;4(8):858-864
pubmed: 20596373
Small. 2009 Aug 17;5(16):1897-910
pubmed: 19437466
Pharmaceutics. 2021 Nov 08;13(11):
pubmed: 34834310
Indian J Microbiol. 2018 Jun;58(2):214-221
pubmed: 29651181
Int J Pharm. 2020 Apr 30;580:119231
pubmed: 32194207
Small. 2005 Aug;1(8-9):841-4
pubmed: 17193536
Chem Rev. 2005 Apr;105(4):1025-102
pubmed: 15826010
Chem Soc Rev. 2012 Apr 7;41(7):2849-66
pubmed: 22182959
Molecules. 2020 Jun 09;25(11):
pubmed: 32527041
R Soc Open Sci. 2020 Mar 11;7(3):191141
pubmed: 32269782
Bioconjug Chem. 2004 Jul-Aug;15(4):897-900
pubmed: 15264879
Biomaterials. 2009 Apr;30(10):1928-36
pubmed: 19131103
J Phys Chem B. 2009 Aug 13;113(32):11179-85
pubmed: 19606833
Int J Pharm. 2017 Jun 15;525(1):71-84
pubmed: 28411141

Auteurs

Syed Mohd Danish Rizvi (SMD)

Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
Molecular Diagnostic & Personalized Therapeutic Unit, University of Ha'il, Ha'il 81442, Saudi Arabia.

Amr Selim Abu Lila (ASA)

Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
Molecular Diagnostic & Personalized Therapeutic Unit, University of Ha'il, Ha'il 81442, Saudi Arabia.

Afrasim Moin (A)

Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
Molecular Diagnostic & Personalized Therapeutic Unit, University of Ha'il, Ha'il 81442, Saudi Arabia.

Talib Hussain (T)

Molecular Diagnostic & Personalized Therapeutic Unit, University of Ha'il, Ha'il 81442, Saudi Arabia.
Department of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.

Mohammad Amjad Kamal (MA)

Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610065, China.
King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.
Enzymoics, Novel Global Community Educational Foundation, 7 Peterlee Place, Hebersham, NSW 2770, Australia.

Hana Sonbol (H)

Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia.

El-Sayed Khafagy (ES)

Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.

Classifications MeSH